IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer

Hutchinson, R. A., Coleman, H. G., Gately, K., Young, V., Nicholson, S., Cummins, R., Kay, E., Hynes, S. O., Dunne, P. D., Senevirathne, S., Hamilton, P. W., McArt, D. G., & Longley, D. B. (2017). IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer. Cell death discovery, 3, [17050]. https://doi.org/10.1038/cddiscovery.2017.50

Published in:
Cell death discovery

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2017 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access
This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: http://go.qub.ac.uk/oa-feedback

Download date:16. Nov. 2023
IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer

Ryan A Hutchinson1, Helen G Coleman2, Kathy Gately3, Vincent Young3, Siobhan Nicholson3, Robert Cummins4, Elaine Kay4, Sean O Hynes5, Philip D Dunne1, Seedevi Senevirathne1, Peter W Hamilton1, Darragh G McArt1,5 and Daniel B Longley1,5

In this study, we developed an image analysis algorithm for quantification of two potential apoptotic biomarkers in non-small-cell lung cancer (NSCLC): FLIP and procaspase-8. Immunohistochemical expression of FLIP and procaspase-8 in 184 NSCLC tumors were assessed. Individual patient cores were segmented and classified as tumor and stroma using the Definition Tissue Studio. Subsequently, chromogenic expression of each biomarker was measured separately in the nucleus and cytoplasm and reported as a quantitative histological score. The software package pROC was applied to define biomarker thresholds. Cox proportional hazards analysis was applied to generate hazard ratios (HRs) and associated 95% CI for survival. High cytoplasmic expression of tumoral (but not stromal) FLIP was associated with a 2.5-fold increased risk of death in lung adenocarcinoma patients, even when adjusted for known confounders (HR 2.47, 95% CI 1.14–5.35). Neither nuclear nor cytoplasmic tumoral procaspase-8 expression was associated with overall survival in lung adenocarcinoma patients; however, there was a significant trend (P for trend = 0.03) for patients with adenocarcinomas with both high cytoplasmic FLIP and high cytoplasmic procaspase-8 to have a multiplicative increased risk of death. Notably, high stromal procaspase-8 expression was associated with a reduced risk of death in lung adenocarcinoma patients (adjusted HR 0.31, 95% CI 0.15–0.66). On further examination, the cells with high nuclear procaspase-8 were found to be of lymphoid origin, suggesting that the better prognosis of patients with tumors with high stromal nuclear procaspase-8 is related to immune infiltration, a known favorable prognostic factor. No significant associations were detected in analysis of lung squamous cell carcinoma patients. Our results suggest that cytoplasmic expression of FLIP in the tumor and nuclear expression of procaspase-8 in the stroma are prognostically relevant in non-small-cell adenocarcinomas but not in squamous cell carcinomas of the lung.

INTRODUCTION

Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer diagnoses and is the most common cause of death from cancer globally.1–3 The AJCC/UICC-TNM system remains the gold standard for assessing patient prognosis; however, it gives no prediction for treatment benefit. NSCLC has one of the lowest 5-year survival rates of all cancers; therefore, the discovery of new biomarkers that can be used as predictive, prognostic, therapeutic or diagnostic tools is of increasing importance. Over the years, numerous molecular pathways and processes have been identified that underpin lung cancer pathogenesis.4–9 One of the most investigated mechanisms in cancer research has been apoptosis, which frequently becomes dysregulated and contributes significantly to both disease progression and drug resistance.10,11 Apoptosis is an essential physiological mechanism that regulates cell proliferation and tissue homeostasis, which is why its dysregulation is one of the hallmarks of cancer.

Fas-associated death domain-like interleukin 1β-converting enzyme (FLICE)-inhibitory protein (FLIP) is a major apoptosis inhibitor, and its overexpression inhibits the activation of caspase-8 (FLICE)-mediated apoptosis.12 Clinical analyses have revealed that FLIP is frequently overexpressed in many cancers, including NSCLC.12 In addition, previous studies have shown that FLIP expression correlates with tumoral metastatic potential, which may be related to its ability to inhibit anoikis, a form of cell death induced following detachment of anchorage-dependent cells from their extracellular matrix.13,14 Procaspase-8 is an initiator caspase that has been found to be inactivated through epigenetic or genetic mechanisms in a subset of human cancers, such as small-cell lung cancer (SCLC); however, the majority of solid tumors appear to retain procaspase-8 expression or even have elevated procaspase-8 expression compared with adjacent normal tissues.15 Although the reasons for this are unclear, retention or elevation of procaspase-8 levels may be selected for during tumorigenesis or therapeutic intervention, because in complex with the long FLIP splice form (FLIPL), procaspase-8 suppresses another form of cell death termed programmed necrosis or ‘necroptosis’.16,17 Thus a delicate interplay exists between FLIP and procaspase-8 that is critical for regulating at least two major forms of cell death and that can therefore have a major impact on disease progression and response to a range of anticancer therapeutics. For example, we have previously demonstrated in several cancers including NSCLC that downregulating FLIP enhances chemotherapy-induced apoptosis in a caspase-8...
dependent manner, whereas overexpression of FLIP blocks caspase-8-mediated apoptosis.\textsuperscript{15,18,19} NSCLC consists of several histological subtypes, of which adenocarcinoma and squamous cell carcinoma predominate.\textsuperscript{20} In this study, we used a digital pathology approach for measuring FLIP and procaspase-8 expression in the cytoplasmic and nuclear compartments of NSCLC tissues. Because of the increasingly recognized importance of the tumor microenvironment, we also determined the expression of both proteins in the adjacent stromal regions. Our findings indicate that high cytoplasmic FLIP expression in tumor cells is an important determinant of patient prognosis for non-small-cell adenocarcinoma but not for squamous carcinoma. Moreover, we unexpectedly found that high nuclear expression of procaspase-8 in the stromal compartment is strongly associated with improved prognosis.

RESULTS

Automated quantification of FLIP and procaspase-8

A tissue microarray (TMA) was constructed using normal and tumor tissues from a cohort of 184 NSCLC patients and immunohistochemically assessed for the expression of FLIP and procaspase-8.\textsuperscript{21} To achieve both automated quantification and to obtain a continuous range of FLIP and procaspase-8 staining intensities, the TMA images were imported into Definiens Tissue Studio (Definiens AG, Munich, Germany), an image analysis software platform that supports the design, development and application of new image analysis algorithms. For each of the biomarkers being investigated in this study, a novel image analysis method was created using the following steps:

1. Automated tumor identification. Once imported into Definiens, a custom grid was defined to match the layout of the TMA. Patient clinical metadata were linked to each core, and the cores were then digitally ‘de-arrayed’ to generate individual cores and assign array coordinates to match the layout of the original TMA (Figure 1a). Twelve of the de-arrayed cores, which demonstrated a range of biomarker expression positivity, were used in a training set (Figure 1a). First, a threshold to distinguish between background and whitespace was defined using a combination of thresholds, which included a homogeneity threshold that segmented the image into homogeneous and non-homogeneous regions. These segmented regions were then classified as background and tissue core; additionally, a minimum area parameter that classified artifacts as part of the background was included. Each individual tissue core was segmented into super-pixels using a multi-resolution segmentation algorithm (Figure 1b), which partitioned the image into spectrally coherent regions. Within each super-pixel, the brown chromogen intensity, hematoxylin intensity, area and shape as well as customized arithmetic (ratios of hematoxylin to brown chromogen intensity) and temporo-spatial features (distance of tumor regions to stroma and whitespace) were measured. Using these features, in combination with a machine learning approach, each super-pixel was classified as either tumor or stroma (Figure 1c). From each of these classified super-pixels, nuclei, cytoplasm and cell boundaries were identified (Figure 1d). This subsequently allowed the separate quantitative analysis of protein expression in both the tumor and stromal compartments. Before the algorithm was applied across the complete patient cohort, an experienced Pathologist confirmed that the identification and classification of regions was accurate in an independent training set.

2. Detection and classification of tumoral and stromal nuclei. A stain deconvolution algorithm was used to separate the DAB chromogen stain and the hematoxylin counterstain in all tissue cores. Using super-pixels to define tissue compartments, thresholds were identified to distinguish between positive and negative nuclear expression of each protein using the image object information table within the software. Nuclei were segmented on a nucleus-by-nucleus basis, which enabled visualization of multi-parametric features of each individual nucleus (Figure 1d). The image object table enables the identified nuclei to be sorted by features of interest; in this case, morphology, hematoxylin intensity and brown chromogen intensity were used. From these features, brown chromogen intensity and hematoxylin intensity thresholds were determined, and we used these to segment and identify both positive and negative nuclei within the tumor and positive and negative nuclei within stromal regions. Using this information, a nuclei filter was applied, which enabled us to remove nuclei that did not match the morphological and staining criteria. Nuclei were identified based on measures of their size, sphericity, density and level of overlap. A nucleus classification module was added to the algorithm, and using the image object information table, the minimum and maximum brown chromogen intensity of each individual positive nucleus was determined. Nuclei detected using the hematoxylin threshold remained negative when the chromogenically positive nuclei were classified.

3. Identification of cell boundaries and cytoplasmic compartments. In order to be able to assess the cytoplasmic intensity of the proteins, cell simulation was used to ‘grow’ a cytoplasmic compartment for each cell from the detected nucleus. Using the training set, a ‘region of growth’ of 4 μm was identified as the optimal threshold for cell border generation; the growth and morphology of these generated cells were determined through the visualization of a ‘cell mask’. From this cell simulation module, the area between the identified nucleus and cell boundary was classified as cytoplasm. The final stage in the algorithm development was to classify cytoplasmic expression of each biomarker within the regions of interest. The brown chromogen intensity of each individual cytoplasmic region was used to determine the threshold for cytoplasmic expression of each biomarker.

4. Determination of a compartment-specific biomarker histological score (H-score). From the segmented and classified tumoral and stromal cells, the expression was quantified in each compartment, and using brown chromogen intensity and hematoxylin intensity thresholds, a H-score was calculated for nuclear and cytoplasmic FLIP and procaspase-8 using the formula: (1 × percentage of low brown chromogen intensity-positive cells) + (2 × percentage of medium brown chromogen intensity-positive cells) + (3 × percentage of high brown chromogen intensity-positive cells) based on the quantitative data generated from the image analysis algorithm. Utilizing Definiers Image Miner 2.0 (Definiens AG, Munich, Germany), we created a customized data repository, which linked the clinicopathological data with the quantitative image analysis data. When the algorithm was applied across each TMA, a quality control step was adopted to ensure the algorithm was performing robustly and was not specific to the training set. Random cores were selected from each analyzed TMA, and the tumor identification method, cellular segmentation and quantification were checked by two of the study investigators (RAH and PWH).

High cytoplasmic FLIP in tumor cells is an adverse prognostic marker in adenocarcinoma

Table 2 shows the association between overall survival of lung adenocarcinoma patients and the expression of tumoral and stromal FLIP and procaspase-8 expression within the nucleus and cytoplasm. High cytoplasmic expression of tumoral FLIP (H-score > 172.5) was associated with a two-fold increased risk of death in lung adenocarcinoma patients, which strengthened further when adjusted for known confounders (HR 2.47, 95% CI 1.14–5.35;
High tumoral FLIP nuclear expression (H-score > 105) was also associated with an increased risk of death, although this did not achieve statistical significance. In contrast, higher stromal FLIP expression in the nucleus and cytoplasm was associated with non-significant decreased risks of death.

High nuclear caspase-8 in stroma is a favorable prognostic marker in adenocarcinoma

Neither nuclear nor cytoplasmic tumoral procaspase-8 expression was associated with overall survival in lung adenocarcinoma patients. Unexpectedly, however, high stromal nuclear procaspase-8 expression (H-score > 90.5) was associated with a reduced risk of death in lung adenocarcinoma patients, which was significant when considering nuclear expression (adjusted HR 0.31, 95% CI 0.15–0.66; Table 2, Figure 2b). Results remained largely similar in sensitivity analysis excluding patients who died in the first 6 months of follow-up (data not shown). There was also a similar trend with high stromal cytoplasmic procaspase-8 expression (H-score > 139.5), although this did not reach significance (adjusted HR 0.51, 95% CI 0.23–1.11). Under further pathological examination (RAH, SH, PWH), the stromal cells expressing high procaspase-8 had clear lymphoid cell characteristics, suggesting that high stromal procaspase-8 expression identifies tumors with high degree of immune infiltration.

Notably, no significant associations between overall survival of lung squamous cell carcinoma patients and expression levels of either protein in the nucleus or cytoplasm of tumor or stroma were observed (Table 3), suggesting that FLIP and procaspase-8 are more relevant in non-small-cell lung adenocarcinomas.
Given that FLIP is a key modulator of procaspase-8 activation in the cytoplasm and that these proteins are transcribed from the same genetic locus (2q33-q34), we examined whether there was a correlation between their expression at the protein level. In the overall patient cohort, there was no significant correlation between expression of the two proteins; however, in the squamous (but not the adenocarcinoma) subset, a significant positive correlation was observed ($r = 0.25, P = 0.02$; Figure 3a). We further determined whether combined assessment of cytoplasmic FLIP and caspase-8 expression had prognostic relevance. Although, no significant associations between individual combined categories and death were observed, there was a significant trend ($P$ for trend = 0.03) for patients with adenocarcinomas with FLIP/procasase-8 correlation and combined prognostic relevance.
both high cytoplasmic FLIP and high cytoplasmic procaspase-8 having a multiplicative increased risk of death; however, no such association was observed in the squamous histology subgroup (Figure 3b).

**DISCUSSION**

Procasppase-8 and its endogenous inhibitor FLIP are key regulators of the extrinsic apoptotic pathway activated by cell surface death receptors and are also key regulators of cell death induced by cytoplasmic complexes, such as the ripoptosome.1,2,22 We have previously reported that FLIP and procaspase-8 expression are key determinants of response to chemotherapy and ionizing radiation in preclinical models of NSCLC.12,22 We therefore used a digital pathology approach to evaluate nuclear and cytoplasmic FLIP and procaspase-8 expression in a cohort of NSCLCs containing both adenocarcinoma and squamous cell carcinoma histological subtypes.

By defining H-score cutoffs using the ROC approach and by performing multivariate analyses that demonstrate that cytoplasmic FLIP expression is an independent prognostic factor in adenocarcinoma patients but not in squamous cell carcinoma patients, this study refines our previous findings that high cytoplasmic FLIP expression is a biomarker of poor prognosis in NSCLC.23 Of note, nuclear FLIP expression was not significantly prognostic in adenocarcinoma patients, highlighting the value of analyzing protein expression at a subcellular level. Our previous analysis of this patient cohort using a generic method for scoring procaspase-8 failed to identify the prognostic significance of nuclear procaspase-8 in the stromal compartment that was revealed in this study, further underlining the potential utility of this methodological approach.

As a major inhibitor of cell death induced by death ligands expressed by immune effector cells, high FLIP expression has been shown to promote immune escape of tumors in mouse models.24 Hence, it is plausible that FLIP overexpression is selected for during tumorigenesis to enable tumor cells evade immune elimination via apoptosis. Also, as noted above, FLIP confers resistance to chemotherapy- and ionizing radiation-induced apoptosis,15,23 which is again consistent with the association that we have observed between high FLIP expression and poor prognosis. Unlike SCLCs, which frequently lose procaspase-8 expression,25 NSCLCs tend to maintain or even overexpress procaspase-8.15 This may be driven by the necessity to suppress another form of cell death, necroptosis; procaspase-8 and FLIP form an enzymatic complex, which although lacking the ability to promote apoptosis, can cleave receptor-interacting kinase-1, a key mediator of necroptosis.22

We have previously demonstrated that depletion of FLIP using histone deacetylase (HDAC) inhibitors, such as Entinostat, which has recently been FDA approved for the treatment of aromatase inhibitor-resistant, estrogen receptor-positive breast cancer, results in caspase-8-dependent apoptosis induction and enhances the antitumor effects of chemotherapeutic agents, ionizing radiation and TRAIL.15,21,23 The results presented here suggest that HDAC inhibitors or other agents that target FLIP could potentially be targeted against poor prognostic lung adenocarcinomas expressing high cytoplasmic levels of FLIP. Similarly, tumors with low cytoplasmic FLIP expression may be effectively targeted with TRAIL receptor-targeted therapeutics, the second generation of which are in preclinical and clinical development.26,27 Another emerging targeted therapy are the IAP antagonists (also referred to as SMAC mimetics),28 which we have shown are dependent on FLIP for their efficacy,29 thus these agents may also be most effective in NSCLCs with low cytoplasmic FLIP expression.

Given their close biological relationship, we assessed the correlation between FLIP and procaspase-8 protein expression and their combined prognostic relevance. Although cytoplasmic expression of FLIP and procaspase-8 were more strongly correlated in squamous cell carcinomas, the combined expression of these proteins was more prognostic in adenocarcinoma. Of note, high nuclear procaspase-8 expression was apparent in cells of lymphoid morphology in the stroma of tumors of adenocarcinoma patients with good prognosis. Although predominantly expressed in the cytoplasm, sumoylated caspase-8 translocates to the nucleus.30 Moreover, caspase-8 has been reported to have a broad role in the activation of immune cells; for example, caspase-8 has been shown to be essential for T-cell proliferation, as specific deletion of the gene encoding caspase-8 (CASP8) in T cells results in depletion of the peripheral T-cell population, thereby impairing immune responses.12,31,32,33 It is possible that lymphoid cells with high nuclear caspase-8 promote antitumor immunity, which could explain the association between high nuclear procaspase-8 in the stromal compartment and good prognosis. Indeed, high density of CD4 and CD8 positive T cells in cancer stroma has been correlated with longer survival times in NSCLC patients.34,35

In conclusion, this study demonstrates the potential of digital imaging to quantify immunohistochemical expression of putative biomarkers in tumor and stromal compartments at a subcellular level to generate a quantified output, in this case a region-specific H-score. The methodology described herein could ultimately be developed to stratify adenocarcinoma NSCLC patients for therapies that are dependent on FLIP and procaspase-8 expression for their activity.

Table 1. Characteristics of lung cancer patients according to histological subtype

| Characteristic | Adenocarcinoma, n = 86 | Squamous cell carcinoma, n = 89 |
|---------------|------------------------|-------------------------------|
| Age, years, median (range) | 65.7 (42.5–82.7) | 66.0 (41.4–86.2) |
| Sex, n (%) | | |
| Male | 46 (53.5) | 63 (70.8) |
| Female | 40 (46.5) | 26 (29.2) |
| Tumor stage, n (%) | | |
| I | 49 (57.0) | 46 (51.7) |
| II | 14 (16.3) | 26 (29.2) |
| III | 23 (26.7) | 17 (19.1) |
| Tumor grade, n (%) | | |
| I | 9 (10.5) | 2 (2.2) |
| II | 51 (59.3) | 55 (61.8) |
| III | 26 (30.2) | 32 (36.0) |
| Tumor size, cm, median (range) | 3.8 (1–14) | 4.0 (0.9–16) |
| Smoking status | | |
| Current | 26 (30.2) | 26 (29.2) |
| Former | 53 (61.6) | 60 (67.4) |
| Never | 7 (8.1) | 3 (3.4) |
| Surgery type, n (%) | | |
| Lobectomy | 69 (80.2) | 60 (67.4) |
| Bilobectomy | 10 (11.6) | 4 (4.5) |
| Pneumonectomy | 7 (8.1) | 25 (28.1) |
| Vital status by end of follow-up, n (%) | | |
| Alive | 35 (40.7) | 37 (41.6) |
| Dead | 51 (59.3) | 52 (58.4) |
SUBJECTS AND METHODS

Clinicopathological details

The tissue samples used in this study are from a cohort of 184 NSCLC patients (86 adenocarcinomas, 9 other histologies and 89 squamous cell carcinomas) of various stages from St James’ Hospital, Dublin, Ireland. As shown in Table 1, 59 and 58% of lung adenocarcinoma and squamous cell carcinoma patients died by the end of the follow-up period (median 3.8 years, range 0.01–7.4 years), respectively. Nine lung adenocarcinoma and 13 squamous cell carcinoma patients died within the first 6 months, and 16 patients of each histological subtype died within the first year of follow-up. The median age at surgery for lung cancer patients was 66 years. Slightly more males than females were included, particularly in the squamous cell carcinoma group (70.8 versus 29.2%). The majority of lung cancer patients were current or former smokers. The majority of tumors represented early pathological stage (52–57% Stage I), tumor grade II (59–62%) and a median tumor size of approximately 4 cm in both histological subgroups. Most lung adenocarcinoma patients underwent lobectomy (80.2%), with the remainder requiring more extensive surgical resection. The majority of lung squamous cell carcinoma patients also underwent lobectomy (67.4%); however, a greater proportion of this patient group required pneumonectomy compared with adenocarcinoma patients (28.1 versus 8.1%).

Immunohistochemical detection methods

Anti-caspase-8 (1186, Leica Microsystems, Milton Keynes, UK) and anti-FLIP (G-11, Santa Cruz, Heidelberg, Germany) antibodies were used as previously described, with hematoxylin used as a counterstain.36

Digital image acquisition

The TMAs were comprised of three tumor cores and three cores of adjacent normal stroma for each patient. Following immunohistochemical staining, each TMA was digitally scanned at high resolution in the Digital Pathology Laboratory, Northern Ireland Molecular Pathology Laboratory within the centre for Cancer Research and Cell Biology, Queen’s University, Belfast, UK. The slides were scanned using an Aperio ScanScope CS (Aperio Technologies, San Diego, CA, USA) at a resolution of 40x using the objective 40x/0.75 Plan Apo with a doubler and loaded onto the local drive for storage.

Statistical analyses

To define H-score cutoff values, we adopted the approach described by Zlobec et al.37 for using the receiver operating characteristic (ROC). Using R statistical environment version 2.3.3, we employed the pROC software package to determine the sensitivity and specificity of H-score cutoff values for each marker (Tables 2 and 3), with subsequent validation of the most discriminatory cutoffs assessed using Kaplan–Meier curves derived using the survival package within pROC (R Core Team: https://www.r-project.org/38).

Descriptive characteristics and overall survival of patients were evaluated according to histological subtype of lung tumor (adenocarcinoma or squamous cell carcinoma). Cox proportional hazards analysis was conducted exploring risk of death in lung adenocarcinoma or squamous cell carcinoma patients, according to their expression levels of FLIP and procaspase-8 in the tumoral nucleus or cytoplasm or the stromal nucleus or cytoplasm. Analysis was conducted prior to and after adjustment for potential confounders, such as age, sex, smoking status, tumor stage, tumor grade, tumor size and extent of surgical resection conducted. Follow-up was defined as the date of surgery up to the date of death or last known date of vital status. To explore the influence of early deaths in the associations observed, sensitivity analysis was conducted after removing lung cancer patients who died within the first 6 months of follow-up. Cox proportional hazards analysis was conducted in Stata Version 11.2 (StataCorp, College Station, TX, USA). Based on a priori biological plausibility, stratified analysis of risk of death in combined

Table 2. Risk of death in lung adenocarcinoma patients according to FLIP and procaspase-8 expression within the nucleus and cytoplasm in tumor and stromal compartments

|                     | Alive, n = 35 (%) | Dead, n = 51 (%) | Unadjusted hazard ratios (95% confidence intervals) | Adjusted* hazard ratios (95% confidence intervals) |
|---------------------|------------------|-----------------|-----------------------------------------------------|--------------------------------------------------|
| **Tumoral FLIP nucleus** |                  |                 |                                                     |                                                  |
| Low (<=105)         | 24 (68.6)        | 27 (52.9)       | 1.00                                                | 1.00                                             |
| High (>105)         | 11 (31.4)        | 24 (47.1)       | 1.62 (0.93–2.81)                                    | 1.50 (0.81–2.81)                                  |
| **Tumoral FLIP cytoplasm** |              |                 |                                                     |                                                  |
| Low (<=172.5)       | 15 (42.9)        | 11 (21.6)       | 1.00                                                | 1.00                                             |
| High (>172.5)       | 20 (57.1)        | 40 (78.4)       | 1.97 (1.01–3.84)                                    | 2.47 (1.14–5.35)                                  |
| **Stromal FLIP nucleus** |              |                 |                                                     |                                                  |
| Low (<=74.5)        | 18 (51.4)        | 31 (60.8)       | 1.00                                                | 1.00                                             |
| High (>74.5)        | 17 (48.6)        | 20 (39.2)       | 0.79 (0.45–1.39)                                    | 0.75 (0.40–1.41)                                  |
| **Stromal FLIP cytoplasm** |              |                 |                                                     |                                                  |
| Low (<=144.5)       | 17 (48.6)        | 33 (64.7)       | 1.00                                                | 1.00                                             |
| High (>144.5)       | 18 (51.4)        | 18 (35.3)       | 0.65 (0.36–1.15)                                    | 0.57 (0.30–1.08)                                  |
| **Tumoral procaspase-8 nucleus** |          |                 |                                                     |                                                  |
| Low (<=73.5)        | 6 (17.1)         | 16 (31.4)       | 1.00                                                | 1.00                                             |
| High (>73.5)        | 29 (82.9)        | 35 (68.6)       | 0.65 (0.36–1.18)                                    | 0.94 (0.40–2.19)                                  |
| **Tumoral procaspase-8 cytoplasm** |            |                 |                                                     |                                                  |
| Low (<=155.5)       | 14 (40.0)        | 16 (31.4)       | 1.00                                                | 1.00                                             |
| High (>155.5)       | 21 (60.0)        | 35 (68.6)       | 1.25 (0.69–2.27)                                    | 1.57 (0.75–3.31)                                  |
| **Stromal procaspase-8 nucleus** |           |                 |                                                     |                                                  |
| Low (<=90.5)        | 15 (42.9)        | 39 (76.5)       | 1.00                                                | 1.00                                             |
| High (>90.5)        | 20 (57.1)        | 12 (23.5)       | 0.40 (0.21–0.76)                                    | 0.31 (0.15–0.66)                                  |
| **Stromal procaspase-8 cytoplasm** |          |                 |                                                     |                                                  |
| Low (<=139.5)       | 22 (62.9)        | 42 (82.4)       | 1.00                                                | 1.00                                             |
| High (>139.5)       | 13 (37.1)        | 9 (17.7)        | 0.51 (0.25–1.05)                                    | 0.51 (0.23–1.11)                                  |

*Adjustments included age, sex, smoking status, TNM stage, tumor size, tumor grade and surgery type.
categories of high and low cytoplasmic FLIP and procaspase-8 expression was
evaluated.

ACKNOWLEDGEMENTS
We thank Dr Bjoern Reiss from Definiens AG, Munich, Germany for all technical
and support throughout the study.

COMPETING INTERESTS
The authors declare no conflict of interest.

PUBLISHER’S NOTE
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

REFERENCES
1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer
statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
2 Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The International
Epidemiology of Lung Cancer: latest trends, disparities, and tumor characteristics.
J Thorac Oncol 2016; 11: 1653–1671.
3 Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer:
epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83:
584–594.
4 Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. Somatic
mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:
1069–1075.
5 Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or
 carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:
947–957.
6 Engelman JA, Zejnnllahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET
amplification leads to gefitinib resistance in lung cancer by activating ERBB3
signaling. Science 2007; 316: 1039–1043.
7 Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. Identification
of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Nature 2007; 448: 561–566.
8 Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol
2011; 12: 175–180.
9 Cancer Genome Atlas Research Network. Comprehensive molecular profiling of
lung adenocarcinoma. Nature 2014; 511: 543–550.
10 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;
144: 646–674.
11 Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resis-
tance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714–726.
12 Riley JS, Malik A, Holohan C, Longley DB. DED or alive: assembly and regulation of
the death effector domain complexes. Cell Death Dis 2015; 6: e1866.
13 Mawji IA, Simpson CD, Gronda M, Williams MA, Hurden R, Henderson CJ et al. A
chemical screen identifies anisomycin as an anisok with functions that by
decreasing FLIP protein synthesis. Cancer Res 2007; 67: 8307–8315.
14 Mawji IA, Simpson CD, Hurden R, Gronda M, Williams MA, Filmus J et al. Critical
role for Fas-associated death domain-like interleukin-1-converting enzyme-like
inhibitory protein in anisok resistance and distant tumor formation. J Natl Cancer
Inst 2007; 99: 811–822.
15 Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O’Byrne K et al.
Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis
induced by FLIP silencing. Cell Death Differ 2009; 16: 1352–1361.
16 Vanden Berghe T, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens
et al. Necroptosis, necrosis and secondary necrosis converge on similar
cellular disintegration features. Cell Death Differ 2010; 17: 922–930.
FLIP and procaspase-8 in NSCLC
RA Hutchinson et al.

17 He MX, He YW. A role for c-FLIP(L) in the regulation of apoptosis, autophagy, and necroptosis in T lymphocytes. Cell Death Differ 2013; 20: 188–197.

18 Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L et al. c-FLIP inhibits chemotherapeutically-induced colorectal cancer cell death. Oncogene 2006; 25: 838–848.

19 Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM et al. c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 2007; 67: 5754–5762.

20 Langer CJ, Besse B, Gualberto A, Brambilla E, Sonia JC. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: S311–S320.

21 Riley JS, Hutchinson et al. Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. Cell Death Dis 2013; 4: e951.

22 Vanden Berghe T, Kaiser WJ, Bertrand MJ, Vandenabeele P. Molecular crosstalk between apoptosis, necroptosis, and survival signaling. Mol Cell Oncol 2015; 2: e975093.

23 Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999; 190: 1033–1038.

24 Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C et al. Immune escape of tumors between apoptosis, necroptosis, and survival signaling. Mol Cell Oncol 2015; 2: e975093.

25 McLaughlin KA, Nemeth Z, Bradley CA, Humphreys L, Stasik I, Fenning C et al. FLIP: a targetable mediator of resistance to radiation in non-small cell lung cancer Mol Cancer Ther 2016; 15: 2432–2441.

26 Medeira JP, de Jong J, van Hall T, Felip E, Offringa R. FLIP regulates the expression of FLICE-inhibitory protein. J Exp Med 1999; 190: 1033–1038.

27 Hopkinson-Dalton S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C et al. Silencing of death receptor and procaspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 2003; 10: 356–364.

28 Greer YE, Tice D, Lipkowitz S. Independent of cross-linking via Fc gamma receptors. J Exp Med 1999; 190: 1033–1038.

29 Fulda S. Smac mimetics as IAP antagonists. Semin Cell Dev Biol 2015; 39: 132–138.

30 Besnault-Mascard L, Leprince C, Auffredou MT, Meunier B, Bourgeade MF, Camonis J et al. Caspase-8 sumoylation is associated with nuclear localization. Oncogene 2005; 24: 3268–3273.

31 Salmena L, Hakem R. Caspase-8 deficiency in T cells leads to a lethal lymphoproliferative immune disorder. J Exp Med 2005; 202: 727–732.

32 Lu JV, Weist BM, van Raam BJ, Marro BS, Nguyen LV, Srinivas P et al. Complementary roles of Fas-associated death domain (FADD) and receptor interacting protein kinase-3 (RIPK3) in T-cell homeostasis and antiviral immunity. Proc Natl Acad Sci USA 2011; 108: 15312–15317.

33 Ch’en IL, Tsai JS, Molkentin JD, Komatsu M, Hedinck SM. Mechanisms of necroptosis in T cells. J Exp Med 2011; 208: 633–641.

34 Wakabayashi Y, Yamauchi K, Osumi S, Komura F, Koshita I, Ogura S et al. CD4 + T cells in cancer stroma, not CD8 + T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003; 94: 1003–1009.

35 Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremsnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14: 5220–5227.

36 McLomans DP, Barret HL, Cummins R, McDermott U, McDowell C, Conlon SJ et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010; 16: 3442–3451.

37 Zloibc I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007; 60: 1112–1116.

38 Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77.